Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest & Investment Income (2016 - 2019)

Historic Interest & Investment Income for Corcept Therapeutics (CORT) over the last 7 years, with Q1 2019 value amounting to $1.1 million.

  • Corcept Therapeutics' Interest & Investment Income rose 27312.93% to $1.1 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.5 million, marking a year-over-year increase of 63617.02%. This contributed to the annual value of $3.6 million for FY2022, which is 57240.08% up from last year.
  • Per Corcept Therapeutics' latest filing, its Interest & Investment Income stood at $1.1 million for Q1 2019, which was up 27312.93% from $1.0 million recorded in Q4 2018.
  • Corcept Therapeutics' 5-year Interest & Investment Income high stood at $1.1 million for Q1 2019, and its period low was -$487000.0 during Q3 2016.
  • For the 4-year period, Corcept Therapeutics' Interest & Investment Income averaged around $255272.7, with its median value being $188000.0 (2017).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first soared by 11765.91% in 2017, then skyrocketed by 78255.81% in 2018.
  • Corcept Therapeutics' Interest & Investment Income (Quarter) stood at -$410000.0 in 2016, then surged by 145.85% to $188000.0 in 2017, then soared by 454.26% to $1.0 million in 2018, then rose by 5.28% to $1.1 million in 2019.
  • Its Interest & Investment Income was $1.1 million in Q1 2019, compared to $1.0 million in Q4 2018 and $759000.0 in Q3 2018.